Brief: Pacira Biosciences Receives FDA 510K Clearance For New Iovera° Smarttip To Manage Chronic Low Back Pain Via Long-Lasting Medial Branch Nerve Block
07/01/2025 13:06
Jan 7 (Reuters) - Pacira Biosciences Inc PCRX.O :
* PACIRA BIOSCIENCES RECEIVES FDA 510K CLEARANCE FOR NEW
IOVERA°
SMARTTIP TO MANAGE CHRONIC LOW BACK PAIN VIA LONG-LASTING MEDIAL
BRANCH NERVE BLOCK
Source text: ID:nGNXllxzg
Further company coverage: PCRX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Pacira BioSciences
See all newsUS STOCKS ON THE MOVE-Palantir, Haemonetics
U.S. STOCKS ON THE MOVE-Palantir, Haemonetics, Starbucks
Pacira BioSciences jumps on $1.65 billion Viatris buyout deal
Brief: Viatris - Pacira To Pay Viatris $62 Million Termination Fee Under Specified Circumstances
Pacira BioSciences jumps on $1.65 billion Viatris buyout deal